The magnitude of structural biology and omics information arriving at the service of drug discovery and medicinal chemistry research is expediting the rate of hit-to-lead development . However, harnessing this deluge of information to identify optimal drug targets poses a multifaceted challenge. The efficacy and success of drug development largely hinges upon precise target identification, necessitating innovative technologies to address these challenges. Covalent inhibitors, long overlooked due to concerns about reactivity and off-target effects , are now gaining substantial attention and reverence in both academic and pharmaceutical drug design programs.